No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
OLMA240517P7500
- 0.05
- -0.25-83.33%
15min DelayTrading May 15 11:10 ET
0.10High0.05Low
0.10Open0.30Pre Close265 Volume9 Open Interest7.50Strike Price1.60KTurnover236.97%IV-26.82%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type-0.0544Delta0.0549Gamma203.60Leverage Ratio-0.0360Theta0.0000Rho-11.07Eff Leverage0.0009Vega
Intraday
- 5D
- 1D
News
OPEN, BCRX and AWIN Among Pre-market Gainers
Olema Pharmaceuticals Announces Promising Breast Cancer Trial Results
Express News | Olema Oncology Announces Interim Results From Phase 1b/2 Palazestrant Study, Says 85% Clinical Benefit Rate Observed To Date Across All CBR-Eligible Patients
Express News | Olema Reports 85% Cbr in Breast Cancer Drug Study
Express News | Olema Pharmaceuticals: Across 50 Treated Patients, Palazestrant (Op-1250) Plus Ribociclib Was Well Tolerated With No New Safety Signals
Express News | Olema Oncology Announces Promising New Data for Palazestrant in Combination With Ribociclib Presented at the 2024 Esmo Breast Cancer Congress
Comments
Although the sale doesn't necessarily signify a negative view on the company's future, absence of insider buying could induce concerns. Other company risks should be considered when investing.
President Sean Bohen Sold A Bunch Of Shares In Olema PharmaceuticalsMr. Garland's expertise in biopharma is predicted to boost late-stage development of Olema's lead product. This could solidify the company's influence in shaping next-gen therapies for women's cancers.
$Olema Pharmaceuticals(OLMA.US$ Olema Pharmaceuticals Announced New Preclinical Data Regarding The Discovery Of Novel Compounds Targeting KAT6, An Epigenetic Target That Is Dysregulated In Breast And Other Cancers
2
Read more